Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06238349
Other study ID # GWu
Secondary ID NKRDRC/2022YFC27
Status Recruiting
Phase Phase 4
First received
Last updated
Start date January 23, 2024
Est. completion date June 28, 2024

Study information

Verified date February 2024
Source Zhuhai Center for Maternal and Child Health Care
Contact Gaohong Wu, M.M.
Phone +8617841565295
Email 1217555215@qq.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the efficacy and safety of sunbathing and Bifidobacterium alone or in combination for full-term neonates with hyperbilirubinemia. The investigators hypothesize that the combination therapy of sunbathing plus Bifidobacterium is safe and effective for prevention and management of hyperbilirubinemia in full-term neonates. The investigators therefore design this prospective, randomized, controlled study to assess the preventive effects of sunbathing combined with Bifidobacterium supplementation on hyperbilirubinemia in full-term neonates. These observations may provide scientific evidence for the use of sunbathing and Bifidobacterium supplementation in the management of hyperbilirubinemia in full-term neonates.


Description:

To evaluate the efficacy and safety of sunbathing and Bifidobacterium alone or in combination for full-term neonates with hyperbilirubinemia. The investigators hypothesize that the combination therapy of sunbathing plus Bifidobacterium is safe and effective for prevention and management of hyperbilirubinemia in full-term neonates. The investigators therefore design this prospective, randomized, controlled study to assess the preventive effects of sunbathing combined with Bifidobacterium supplementation on hyperbilirubinemia in full-term neonates. A total of 200 neonates treating in Zhuhai Center for Maternal and Child Health Care from Jan. 2024 to Jun. 2024 will be randomized assigned to either trial groups (receiving sunbathing and Bifidobacterium either alone or in combination) or control group receiving traditional therapy. The primary outcome is the incidence of the hyperbilirubinemia and the secondary outcomes include the hospitalization rate, the hospital stays due to hyperbilirubinemia, and the bilirubin levels. Statistical analyses will be performed using ANOVA or chi-square tests, and further pairwise comparisons will be performed using the Bonferroni correction.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date June 28, 2024
Est. primary completion date June 21, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group N/A to 1 Day
Eligibility Inclusion Criteria: - Term infants with 37 weeks = gestational age < 42 weeks and 2500g = birth weight < 4000g - Age =24 hours - Stable basic vital signs - Liver and kidney function normal - No prior use of antibiotics or ecological agents before specimen collection - Healthy mothers during pregnancy, with no history of antibiotics or microecological agents before, during, or after childbirth - Exclusively breastfed - Informed consent provided voluntarily. Exclusion Criteria: - Gestational age <37 weeks or =42 weeks - Complications present with pneumonia, septicemia, or other illness - Severe immunodeficiency disease present - Inherited metabolic diseases identified - Congenital biliary malformations or other organ malformations - Drug allergies - History of asphyxiation - Before enteral feeding, constipation, abdominal distension, diarrhea, vomiting or other gastrointestinal symptoms had appeared - Enteral feeding was not performed - Antibiotics or other microecological agents were used - Isoimmune hemolysis, extravascular hemolysis, polycythemia, erythrocyte enzyme deficiency, erythrocyte morphological abnormality, hemoglobinopathy, etc. - Hyperbilirubinemia were diagnosed within 24 hours of birth - Situations that may warrant exclusion as determined by the researcher, such as a guardian with mental illness or frequent changes in living or working environments, which might result in loss of follow-up

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Oral bifidobacterium triple live powder
The newborns in the Bifidobacterium group will receive all interventions prescribed for the control group, and also were assigned to orally be given Bifidobacterium triple viable powder (Shanghai Xinyi Pharmaceutical Company, Peifeikang powder, 0.5 g/dose, 3 times/day. Bifidobacterium triple viable powder contains live bacteria of long Bifidobacterium at no less than 1.0 × 107 CFU/g, stored at 2.8? away from light) beginning within 24 hours after birth and continuing for 1 week. No sunbathing will be prescribed.
Other:
Sunbathing
The sunbathing group will receive all interventions prescribed for the control group and be assigned to sunbathing (placement in a bed next to a sunny window) after birth for one week according to the following plan: Every morning and afternoon neonates sunbath for 0.5 to 1 hour to avoid excess sun exposure. Healthcare workers will guide and assist families in their preparations. The caregiver will place a black eye patch on the infants to protect the retina, and a cloth will be wrapped around the hands and feet to prevent scratching, but care will be taken that the wrap is not too tight to avoid circulation disorders. Baby boys will have their genitals covered to protect them from sun damage. After feeding, the newborn will be placed on a sunny platform with fully exposed skin and frequent position changes, while the glass of the window prevent injury from UV light exposure.
Sunbathing and the Oral bifidobacterium triple live powder
The combination group will receive all interventions of both the group sunbathing and the Bifidobacterium group as well as all interventions prescribed for the control group.
Conventional treatment
Conventional treatment: Neonates will be placed in an incubator (Ningbo David Medical Device Co., LTD, XHZ model) at 30? and relative humidity at 55%. Throughout the study, exclusive breastfeeding and professional care will be provided for the newborns. Newborns requiring phototherapy receive it in the following manner: Phototherapy eye masks (Foshan Forman Medical Technology Co., LTD., Yuesun Mechanical Equipment No. 20160015) and phototherapy diapers (Foshan Baojusheng Medical Equipment Co., LTD., GB/T33280) will be used to cover the eyes and perineum, respectively. Phototherapy was provided via LED blue light continuous irradiation with a wavelength of 425-475nm. All treated neonates will receive continuous phototherapy for 12 hours, then allowe to rest for 6-8 hours, then receive another 12 hours of continuous phototherapy. The decision to continue with further treatment depends on changes in the neonate's jaundice.

Locations

Country Name City State
China Zhuhai Center for Maternal and Child Health Care Zhuhai Guangdong

Sponsors (2)

Lead Sponsor Collaborator
Zhuhai Center for Maternal and Child Health Care Children's Hospital of Chongqing Medical University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Numbers of participants with adverse event Neonates in the intervention groups will be monitored for potential side effects, including rash, infection, diarrhea, dehydration, and electrolyte disturbances. From 1 to 7 days after birth
Other Numbers of participants with single or multiple births Single or multiple births will be collected and compared. From 1 to 7 days after birth
Other Numbers of participants with intrauterine distress Intrauterine distress will be collected and compared. From 1 to 7 days after birth
Other Participants's gestational age Gestational age will be collected and compared. From 1 to 7 days after birth
Other Participants's sex Sex will be collected and compared. From 1 to 7 days after birth
Other Participants's delivery mode Delivery mode will be collected and compared. From 1 to 7 days after birth
Other Participants's birth weight Birth weight in kilograms will be collected and compared. From 1 to 7 days after birth
Other Participants's head circumference Head circumference in centimeter will be collected and compared. From 1 to 7 days after birth
Other Participants's birth length Birth length in centimeter will be collected and compared. From 1 to 7 days after birth
Primary Numbers of participants with hyperbilirubinemia Comparisons will be made of the numbers of neonates with hyperbilirubinemia between groups (Sunbathing group vs. Control group, Bifidobacterium group vs. Control group, Combination group vs. Control group, Combination group vs. sunbathing group, Combination group vs. Bifidobacterium group, and Bifidobacterium vs. sunbathing group). From 1 to 7 days after birth
Secondary Rate of hospitalization Comparisons will be made in hospitalization rate in the first week of life between groups (sunbathing group vs. Control group, Bifidobacterium group vs. Control group, Combination group vs. Control group, Combination group vs. sunbathing group, Combination group vs. Bifidobacterium group, and Bifidobacterium vs. sunbathing group). From 1 to 7 days after birth
Secondary Hospital stays due to hyperbilirubinemia Comparisons will be made in hospital stays due to hyperbilirubinemia in the first week of life between groups (sunbathing group vs. Control group, Bifidobacterium group vs. Control group, Combination group vs. Control group, Combination group vs. sunbathing group, Combination group vs. Bifidobacterium group, and Bifidobacterium vs. sunbathing group). From 1 to 7 days after birth
Secondary Participants's bilirubin levels Comparisons will be made in bilirubin levels in the first week of life between groups (sunbathing group vs. Control group, Bifidobacterium group vs. Control group, Combination group vs. Control group, Combination group vs. sunbathing group, Combination group vs. Bifidobacterium group, and Bifidobacterium vs. sunbathing group). From 1 to 7 days after birth
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04868019 - Role of Fenofibrate in Indirect Neonatal Hyperbilirubinemia: a Randomized Control Trial N/A
Completed NCT00114543 - Trial of Aggressive Versus Conservative Phototherapy in Infants <1,000 Grams Birth Weight Phase 3
Completed NCT02000830 - Follow up Study of Patients Having Participated in Clinical Trial 64,185-204
Completed NCT01887327 - Stannsoporfin With Light Therapy for Newborn Babies With Jaundice Phase 2
Completed NCT05356273 - The Effect of Massage on the Bilirubin Level in Term Infants Receiving Phototherapy N/A
Suspended NCT03741803 - Relationship Between Delayed Cord Clamping at Birth and Neonatal Bilirubin Levels in Parturients With a Prior Child Requiring Therapy for Neonatal Jaundice N/A
Recruiting NCT03876678 - The Efficacy of Oral Probiotics on Neonatal Hyperbilirubinemia N/A
Not yet recruiting NCT05365984 - Intelligent Follow-up of Neonatal Jaundice Based on Early Indicators and Internet Communications N/A
Recruiting NCT04251286 - Screening and Follow-up Study of Neonatal Jaundice Based on Mobile Network
Completed NCT03723005 - A Light Emitting Diode (LED) Mattress for Phototherapy of Jaundiced Newborns
Recruiting NCT06087874 - Preventive Effect of Perinatal Oral Probiotic Supplementation (POPS) on Neonatal Jaundice Phase 2
Completed NCT03624335 - Influence of Umbilical Cord Clamping Time in the Newborn N/A
Recruiting NCT06324799 - The Effect of Position Change Frequency on Hyperbilirubinemia N/A
Recruiting NCT06209489 - White Cover and Massage Impact on Bilirubin Levels and Phototherapy Duration in Newborns N/A
Completed NCT03824990 - Multi-center Clinical Study on Neonatal Hyperbilirubinemia N/A
Withdrawn NCT01330667 - Effect of Early Limited Formula on Total Serum Bilirubin Among Newborns With Hyperbilirubinemia N/A
Completed NCT01169740 - Transcutaneous Measurement of Jaundice in the Newborn N/A
Completed NCT03007563 - Evaluation of a Smartphone Based Optical Diagnostic Tool for Neonatal Jaundice N/A
Completed NCT01762189 - The Incidence and Risk Factors of Neonatal Hyperbilirubinemia in Term and Late-preterm Chinese Infants N/A
Completed NCT01763632 - Development of TcB Nomogram to Identify Neonatal Hyperbilirubinemia in Term and Late-preterm Infants N/A